MedTrace Logo

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1600

Last updated 2026-04-30

No results posted yet for this study

Summary

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Conditions

Interventions

BIOLOGICAL

Ivonescimab Injection

Subject will receive ivonescimab and chemotherapy as an IV injection

BIOLOGICAL

Pembrolizumab Injection

Subject will receive pembrolizumab and chemotherapy as an IV injection

Sponsors & Collaborators

  • Summit Therapeutics

    lead INDUSTRY

Principal Investigators

  • Indu Lal · Summit Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-26
Primary Completion
2028-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • China
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Japan
  • Mexico
  • Poland
  • Serbia
  • Spain
  • Sweden
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05899608 on ClinicalTrials.gov